The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience
This study aims to investigate the effect of different local testicular treatments and validate common prognostic factors on primary testicular lymphoma (PTL) patients. We retrospectively reviewed the clinical records of 32 patients from 1993 to 2017 diagnosed with PTL and included 22 patients for a...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
Series: | Asian Journal of Andrology |
Subjects: | |
Online Access: | http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=6;spage=615;epage=620;aulast=Ma |
id |
doaj-0366b7c4f1f84feab741a7e37599e6de |
---|---|
record_format |
Article |
spelling |
doaj-0366b7c4f1f84feab741a7e37599e6de2020-11-25T00:13:43ZengWolters Kluwer Medknow PublicationsAsian Journal of Andrology1008-682X1745-72622018-01-0120661562010.4103/aja.aja_73_18The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experienceRun-Zhuo MaLei TianLi-Yuan TaoHui-Ying HeMin LiMin LuLu-Lin MaHui JiangJian LuThis study aims to investigate the effect of different local testicular treatments and validate common prognostic factors on primary testicular lymphoma (PTL) patients. We retrospectively reviewed the clinical records of 32 patients from 1993 to 2017 diagnosed with PTL and included 22 patients for analysis. The Kaplan–Meier method, Log-rank test, and multivariate Cox proportional hazard regression analysis were applied to evaluate progression-free survival (PFS), overall survival (OS), and determine prognosis predictors. The median follow-up time was 30 months. Median OS and PFS were 96 months and 49 months, respectively. In univariate analysis, advanced Ann Arbor stage (III/IV) (P < 0.001), B symptoms (P < 0.001), and extranodal involvement other than testis (P = 0.001) were significantly associated with shorter OS and PFS. In multivariate analysis, Ann Arbor stage was significantly associated with OS (OR = 11.58, P = 0.049), whereas B symptom was significantly associated with PFS (OR = 11.79, P= 0.049). In the 10 patients with the systemic usage of rituximab, bilateral intervention could improve median OS from 16 to 96 months (P = 0.032). The study provides preliminary evidence on bilateral intervention in testes in the rituximab era and validates common prognostic factors for Chinese PTL patients.http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=6;spage=615;epage=620;aulast=Malocal treatment modalities; prognostic factors; prophylaxis contralateral orchiectomy; prophylaxis contralateral radiotherapy; testicular lymphoma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Run-Zhuo Ma Lei Tian Li-Yuan Tao Hui-Ying He Min Li Min Lu Lu-Lin Ma Hui Jiang Jian Lu |
spellingShingle |
Run-Zhuo Ma Lei Tian Li-Yuan Tao Hui-Ying He Min Li Min Lu Lu-Lin Ma Hui Jiang Jian Lu The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience Asian Journal of Andrology local treatment modalities; prognostic factors; prophylaxis contralateral orchiectomy; prophylaxis contralateral radiotherapy; testicular lymphoma |
author_facet |
Run-Zhuo Ma Lei Tian Li-Yuan Tao Hui-Ying He Min Li Min Lu Lu-Lin Ma Hui Jiang Jian Lu |
author_sort |
Run-Zhuo Ma |
title |
The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience |
title_short |
The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience |
title_full |
The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience |
title_fullStr |
The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience |
title_full_unstemmed |
The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience |
title_sort |
survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience |
publisher |
Wolters Kluwer Medknow Publications |
series |
Asian Journal of Andrology |
issn |
1008-682X 1745-7262 |
publishDate |
2018-01-01 |
description |
This study aims to investigate the effect of different local testicular treatments and validate common prognostic factors on primary testicular lymphoma (PTL) patients. We retrospectively reviewed the clinical records of 32 patients from 1993 to 2017 diagnosed with PTL and included 22 patients for analysis. The Kaplan–Meier method, Log-rank test, and multivariate Cox proportional hazard regression analysis were applied to evaluate progression-free survival (PFS), overall survival (OS), and determine prognosis predictors. The median follow-up time was 30 months. Median OS and PFS were 96 months and 49 months, respectively. In univariate analysis, advanced Ann Arbor stage (III/IV) (P < 0.001), B symptoms (P < 0.001), and extranodal involvement other than testis (P = 0.001) were significantly associated with shorter OS and PFS. In multivariate analysis, Ann Arbor stage was significantly associated with OS (OR = 11.58, P = 0.049), whereas B symptom was significantly associated with PFS (OR = 11.79, P= 0.049). In the 10 patients with the systemic usage of rituximab, bilateral intervention could improve median OS from 16 to 96 months (P = 0.032). The study provides preliminary evidence on bilateral intervention in testes in the rituximab era and validates common prognostic factors for Chinese PTL patients. |
topic |
local treatment modalities; prognostic factors; prophylaxis contralateral orchiectomy; prophylaxis contralateral radiotherapy; testicular lymphoma |
url |
http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=6;spage=615;epage=620;aulast=Ma |
work_keys_str_mv |
AT runzhuoma thesurvivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience AT leitian thesurvivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience AT liyuantao thesurvivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience AT huiyinghe thesurvivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience AT minli thesurvivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience AT minlu thesurvivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience AT lulinma thesurvivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience AT huijiang thesurvivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience AT jianlu thesurvivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience AT runzhuoma survivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience AT leitian survivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience AT liyuantao survivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience AT huiyinghe survivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience AT minli survivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience AT minlu survivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience AT lulinma survivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience AT huijiang survivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience AT jianlu survivalandprognosticfactorsofprimarytesticularlymphomatwodecadesinglecenterexperience |
_version_ |
1725393417246081024 |